Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

/www.incyte.com/.

This press release contains certain forward-looking statements about baricitinib as a potential treatment for patients with rheumatoid arthritis and reflects Lilly and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date, that the product will receive regulatory approval, or, if approved, that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's filings with the United States Securities and Exchange Commission. Lilly and Incyte undertake no duty to update forward-looking statements.

P-LLY

[1] E. Keystone, P. Taylor, M. Genovese, D. Schlichting, S. Beattie, C. Gaich, R. Fidelus Gort, M. Luchi, W.L. Macias. 12-week results of a phase 2b dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor in combination with traditional DMARDS in patients with rheumatoid arthritis. Annals Rheumatic Disease. 2012; 71(Suppl3):152.

[2] M Genovese, E Keystone, P Taylor, P-Y Berclaz, C Lee, D Schlichting, S Beattie, M Luchi, W Macias. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/ janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2012; 64(10(supp)):S1049.

[3] S. Verstovsek. Therapeutic potential of JAK2 inhibitors. American Society of Hematology. 2009: 636.

[4] Arthritis Foundation, What is Rheumatoid Arthritis, http://www.arthritis.org/types-what-is-rheumatoid-arthritis.php (Accessed: May
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, more ... In the military, burn injury is a ubiquitous ... care. More than 800 service members sustained burn ... slowly, remain inflamed and often become infected, producing ... functionally damaging. While developments in supportive care have ...
(Date:9/29/2014)... Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian ... three Promissory Note holders, two of whom are the ... July 2014 for a total of $ 300,000 opted ... 3,500,001 restricted common shares. Notes were repayable within one ... the coupon were convertible into common shares to be ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2
... This release is available in German . ... in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together ... (TUM), have now presented a novel molecular switch in the ... the switch is the position of a single proton in ...
... COLUMBUS, Ohio, Dec. 12, 2011   Chemical Abstracts ... Chemical Society and the world,s authority for chemical ... InfoChem, GmbH (InfoChem), a  leader ... as datamining in chemical science documents, headquartered in ...
... Zyngenia , Inc ... antibody-based drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as ... our start in September 2009, Zyngenia has made tremendous progress in ...
Cached Biology Technology:The smallest conceivable switch 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3
(Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
(Date:9/29/2014)... considered capable of doing anything on their own. But ... water. In the future, such moving droplets may deliver ... to be self-moving is a feature normally ... be self-moving, report researchers from University of Southern Denmark ... , The researchers have made alcohol droplets move in ...
(Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... a telescope promise to make it easier for people ... requiring sharper distance vision. Schepens Eye Research Institute scientists ... devices in an article published in the May/June issue ... in print form to subscribers this month. ...
... A new study by researchers from Columbia University,s ... most challenging issues in infant health and preventing mother-to-child ... HIV-infected mothers had been advised that for the best ... by a rapid weaning four to six months after ...
... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... immune response modifier with potent antiviral and antitumor activity, ... (OGFr) axis for its action. This discovery, reported ... and Medicine , provides new insights into a widely ...
Cached Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
pH-insensitive fluorescence (pH 2-12)...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: